IntegraGen Presents Results of Two Studies during 2015 ASCO Meeting with New Positive Data on the Role of microRNA Biomarker miR-31-3p in Patients with Metastatic Colorectal Cancer

IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced the presentation of two studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting focusing on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with panitumumab or cetuximab. The data presented further validates previous studies which have documented that miR-31-3p expression in the primary tumor of mCRC patients is predictive of the effect of anti-EGFR therapy.

"For the third consecutive year at ASCO we are presenting positive results from studies focusing on miR-31-3p expression in metastatic colorectal cancer patients. The studies presented at this year’s meeting further demonstrate the clinical utility of this single microRNA biomarker to predict the impact of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer patients,” said Bernard Courtieu, IntegraGen’s CEO.

"These studies demonstrate that measurement of the expression of miR-31-3p in a clinical setting will benefit patients, oncologists and payers by increasing the ability to provide a personalized treatment approach to cancer care which avoids ineffective and costly drug therapy and its associated toxicities while also allowing for the earlier utilization of alternative treatment options which may be more effective,” added Pierre Laurent-Puig, M.D., Ph.D., co-author of both studies which were presented at ASCO and Professor, Department of Genetics and Head of the Clinical Oncogenetic Unit at European Georges Pompidou Hospital University Paris Descartes in Paris, France.

INTEGRAGEN obtained the exclusive license for the worldwide rights for the miR-31-3p biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris, all leading French academic institutions which, along with IntegraGen, are co-owners of the patent.

Key Highlights of each Abstract:

"Evaluation of miR-31-3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer: analysis of patients from the PICCOLO trial.”

Link to abstract: http://abstracts.asco.org/156/AbstView_156_146022.html

• Study analyzed miR-31-3p expression and associated outcomes in nearly 200 advanced colorectal cancer (aCRC) patients randomized to receive irinotecan or irinotecan plus panitumumab.
• Patients with lower miR-31-3p expression had significantly better overall and progression free survival (PFS).
• Patients with lower miR-31-3p expression had significantly better tumor response to panitumumab as measured by response rate and disease control.
• Patients with low and intermediate miR-31-3p expression had significant PFS benefit from panitumumab while patients with high expression did not.

"Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.”

Link to abstract: http://abstracts.asco.org/156/AbstView_156_145968.html

• The present study evaluated if miR-31-3p and c-Met expression were associated with the more rapid disease progression seen with cetuximab in the New EPOC study.
• Expression of miR-31-3p and c-Met in primary tumor and matching CLRM were correlated in patients receiving chemotherapy alone (CT) but not in patients exposed to chemotherapy plus cetuximab (CTC).
• Study identified a subgroup of patients who derived significant benefit from cetuximab therapy.
• The loss of correlation between primary tumors and CRLM suggests that cetuximab may modulate miR-31-3p and c-Met expression and that these may be implicated in the mechanism by which earlier progression occurred in these patients.

ABOUT INTEGRAGEN

IntegraGen is a company that specializes in deciphering the human genome and produces relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients.

As of December 31, 2014, IntegraGen had 34 employees and generated revenue of €6 million during 2014. Based in the Evry Genopole, IntegraGen also has an office in the U.S. located in Cambridge, Massachusetts.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150601006356/en/